AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 28th, 2023 • Ocugen, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of December 16, 2021 (the “Effective Date”) by and between Ocugen, Inc., a Delaware corporation (the “Company”), and Arun Upadhyay, Ph.D., an individual (“Employee”).
First Amendment to the EXCLUSIVE LICENSE AGREEMENT between The Washington University and Ocugen, Inc.Exclusive License Agreement • February 28th, 2023 • Ocugen, Inc. • Biological products, (no disgnostic substances)
This first amendment, (“First Amendment”) to the Exclusive License Agreement, WU Contract Number A2023-0203 (hereinafter the “Agreement”), which was made and entered into as of September 23, 2022, is effective as of the date of the last signature below (“First Amendment Effective Date”), by and between The Washington University, through its Office of Technology Management having its principal office at 4240 Duncan Avenue, Suite 110, St. Louis, MO 63110 (hereinafter referred to as “WU”), and Ocugen, Inc., having its principal office at 11 Great Valley Parkway, Malvern, PA 19355 and its affiliates (hereinafter and collectively referred to as “Licensee”). WU and Licensee are referred to herein individually as a “Party” and collectively as the “Parties” of this First Amendment. Capitalized terms that are not defined herein shall have the meaning ascribed to them in the Agreement.
OCUGEN, INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • February 28th, 2023 • Ocugen, Inc. • Biological products, (no disgnostic substances)
THIS INCENTIVE STOCK OPTION AGREEMENT (“Agreement”) is made and entered into as of the ___ day of ____________, 20___ (the “Grant Date”), by and between Ocugen, Inc., a Delaware corporation (the “Company”), and ________________, an individual (the “Optionee”).
OCUGEN, INC. 2019 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE AND RESTRICTED STOCK UNIT AGREEMENTRestricted Stock Unit Grant Notice and Restricted Stock Unit Agreement • February 28th, 2023 • Ocugen, Inc. • Biological products, (no disgnostic substances) • Delaware
Ocugen, Inc (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby grants to the individual listed below (“Participant”) an award of the number of Restricted Stock Units set forth below (the “Restricted Stock Units”). The Restricted Stock Units are subject to the terms and conditions set forth in this Restricted Stock Unit Grant Notice (the “Grant Notice”), the Restricted Stock Unit Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Agreement.
AMENDMENT #1 TO AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 28th, 2023 • Ocugen, Inc. • Biological products, (no disgnostic substances)
WHEREAS, the Company and Employee are parties to an Amended & Restated Executive Employment Agreement dated December 16, 2021 (the “Employment Agreement”);
2nd Amendment to the CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • February 28th, 2023 • Ocugen, Inc. • Biological products, (no disgnostic substances)
This 2nd Amendment to the Co-Development and Commercialization Agreement (the “Second Amendment”) is made by and between Ocugen, Inc., now with an address at 11 Great Valley Parkway, Malvern, PA 19355 (“Ocugen”), and CanSino Biologics Inc., whose registered office address is at 185 South Ave, TEDA West District, Tianjin, 300457, China (“CanSino”), and is effective as of the date of the last signature below (the “Second Amendment Effective Date”). Ocugen and CanSino are hereinafter referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms that are not defined herein shall have the meaning ascribed to them in the Collaboration Agreement (as defined below).
OCUGEN, INC. NON-QUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENTNon-Qualified Stock Option Inducement Award Agreement • February 28th, 2023 • Ocugen, Inc. • Biological products, (no disgnostic substances)
THIS NON-QUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT (“Agreement”) is made and entered into as of _____________ (the “Grant Date”), by and between Ocugen, Inc., a Delaware corporation (the “Company”), and ________________, an individual (the “Optionee”).
OCUGEN, INC. NON-QUALIFIED STOCK OPTION AGREEMENTNon-Qualified Stock Option Agreement • February 28th, 2023 • Ocugen, Inc. • Biological products, (no disgnostic substances)
THIS NON-QUALIFIED STOCK OPTION AGREEMENT (“Agreement”) is made and entered into as of _____________ (the “Grant Date”), by and between Ocugen, Inc., a Delaware corporation (the “Company”), and ________________, an individual (the “Optionee”).
